Neue Tracer und Kombinationen bei der Radioligandentherapie des Prostatakarzinoms

[1]  A. Maes,et al.  225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings , 2023, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  S. Pacey,et al.  Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review , 2023, Cureus.

[3]  M. Stockler,et al.  PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. , 2022, The Lancet. Oncology.

[4]  D. Mueller,et al.  Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation , 2022, Diagnostics.

[5]  Youngho Seo,et al.  CUB domain containing protein 1 (CDCP1) is a target for radioligand therapy in castration resistant prostate cancer including PSMA null disease. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Xiankai Sun,et al.  PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective , 2022, International journal of molecular sciences.

[7]  K. Rahbar,et al.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.

[8]  C. Kratochwil,et al.  Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. , 2020, European urology.

[9]  M. Bartholomä,et al.  225 Ac-PSMA-617/ 177 Lu-PSMA-617 Tandem Therapy of Metastatic Castration-Resistant Prostate Cancer: Pilot Experience , 2019, Nuklearmedizin.

[10]  H. Beltran,et al.  Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer , 2019, Cancer.

[11]  M. Schwaiger,et al.  Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[12]  T. Holland-Letz,et al.  Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Michael Lassmann,et al.  68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies , 2015, The Journal of Nuclear Medicine.